Prerequisites to support high-quality clinical trials in children and young people

Steven Hirschfeld1, Florian B Lagler2,3, Jenny M Kindblom4,5

  • 1Uniformed Services University of the Health Sciences, 4201 Jones Bridge Road, Bethesda, Maryland, 20814 USA.

Insights

Ensuring children receive high-quality medical treatments requires robust paediatric clinical trials. Optimizing trial infrastructure and expertise is crucial for advancing pediatric medicine and ensuring equitable access to new therapies.

Area of Science:

  • Pediatric Research
  • Clinical Trial Design
  • Medical Ethics

Background:

  • Children are often excluded from clinical trials, leading to a knowledge gap in pediatric medicine.
  • This disparity results in children not benefiting from the same quality of evidence-based treatments as adults.
  • Regulatory, scientific, and ethical imperatives exist to address the efficacy and safety of medicines in children.

Purpose of the Study:

  • To identify the necessary structures and competencies for conducting high-quality pediatric clinical trials.
  • To propose a model for optimizing the components of pediatric clinical trials as an integrated ecosystem.
  • To ultimately improve medicines and treatments available for children.

Main Methods:

  • Discussion of essential structural and competency-based prerequisites for pediatric clinical trials.
  • Proposal of an ecosystem model for optimizing individual trial components and their interactions.
  • Emphasis on the integration of the pediatric clinical trial ecosystem with broader research and healthcare systems.

Main Results:

  • Successful pediatric clinical trials require specialized personnel trained in pediatrics and neonatology, with clinical trial expertise.
  • National and international networks are vital for collaboration, information sharing, and resource allocation.
  • Competent local infrastructure, effective processes, and robust monitoring/oversight bodies are critical for trial success.

Conclusions:

  • Optimizing individual components and their synergistic function within an ecosystem is key to effective pediatric clinical trials.
  • A well-functioning pediatric clinical trial ecosystem enhances the general research and healthcare delivery systems.
  • Addressing these structural and competency needs will lead to better medicines and treatments for children.

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.0K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.3K
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.6K
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
68
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
124
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
132